Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials
Open Access
- 9 March 2020
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 4 (4) , 649-655
Abstract
Background Ragweed pollen sensitivity is a common cause of allergic rhinitis (AR) worldwide. AR symptoms include itchy and runny eyes, sneezing, blocked nose, impaired sleep and social and emotional problems, which can have a significant impact on quality of life. Objective The objective of this analysis was to estimate utilities for two pooled standardised quality (SQ) ragweed sublingual immunotherapy (SLIT) tablet trials by applying a previously developed mapping algorithm. This study validated the algorithm and extended its application to ragweed seasonal allergy trials. The mapping algorithm relates disease-specific quality-of-life scores to preference-based utilities that may be used to calculate quality-adjusted life-years (QALYs) in cost-effectiveness studies. Methods A mapping algorithm based on a grass pollen allergy immunotherapy trial, GT-08 (EudraCT no. 2004-000083-27) was applied to pooled data from two ragweed pollen immunotherapy trials, P05233 (EudraCT 2008-003863-38) and P05234 (EudraCT 2008-003864-20) to generate EuroQoL 5-Dimensions, 3-Levels (EQ-5D-3L) utilities from Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) data. Results The mean utility difference between the SQ ragweed SLIT tablet and placebo was 0.025 [95% confidence interval (CI) 0.011–0.038]. The SQ ragweed SLIT tablet showed an incremental quality-adjusted life-days (QALDs) benefit of 1.900 (95% CI 0.835–2.916) over 75 days. Conclusions Application of a previously developed mapping function allowed for the calculation of QALDs associated with the SQ ragweed SLIT tablet. The results showed a QALD benefit of the SQ ragweed SLIT tablet in P05233 and P05234 trials in the treatment of ragweed pollen-induced AR.Keywords
This publication has 29 references indexed in Scilit:
- Ragweed Pollen Allergy: Burden, Characteristics, and Management of an Imported Allergen Source in EuropeInternational Archives of Allergy and Immunology, 2018
- Association between Symptoms of Allergic Rhinitis with Decreased General Health–Related Quality of LifeAmerican Journal of Rhinology & Allergy, 2017
- Burden of allergic respiratory disease: a systematic reviewClinical and Molecular Allergy, 2016
- Allergy immunotherapy: the future of allergy treatmentDrug Discovery Today, 2016
- Common ragweed: A threat to environmental health in EuropeEnvironment International, 2013
- Allergy-related outcomes in relation to serum IgE: Results from the National Health and Nutrition Examination Survey 2005-2006Journal of Allergy and Clinical Immunology, 2011
- Preventing progression of allergic rhinitis: the role of specific immunotherapyArchives of Disease in Childhood - Education & Practice Edition, 2010
- GA2LEN skin test study II: clinical relevance of inhalant allergen sensitizations in EuropeAllergy, 2009
- The voice of the patients: allergic rhinitis is not a trivial diseaseCurrent Opinion in Allergy and Clinical Immunology, 2008
- Economic and quality-of-life impact of seasonal allergic conjunctivitis in OxfordshireOphthalmic Epidemiology, 2004